Literature DB >> 23445368

Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.

Christopher S Hourigan1, Patrick M Forde, Richard F Ambinder, Douglas E Gladstone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23445368      PMCID： PMC4154876          DOI： 10.3109/10428194.2013.780289

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Authors:  Federica Destro; Fabio Sforza; Mariaconcetta Sicurella; Diego Marescotti; Eleonora Gallerani; Anna Baldisserotto; Mauro Marastoni; Riccardo Gavioli
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

2.  GVL for ATL?

Authors:  Nirali N Shah; Thomas A Waldmann
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

3.  Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.

Authors:  Andreas Lundqvist; Su Su; Sheila Rao; Richard Childs
Journal:  J Immunol       Date:  2009-12-21       Impact factor: 5.422

4.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.

Authors:  Ali Bazarbachi; Yves Plumelle; Juan Carlos Ramos; Patricia Tortevoye; Zaher Otrock; Graham Taylor; Antoine Gessain; William Harrington; Gérard Panelatti; Olivier Hermine
Journal:  J Clin Oncol       Date:  2010-06-28       Impact factor: 44.544

5.  EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

Authors:  W H Wilson; G Bryant; S Bates; A Fojo; R E Wittes; S M Steinberg; D R Kohler; E S Jaffe; J Herdt; B D Cheson
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

6.  Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.

Authors:  Y Satou; K Nosaka; Y Koya; J-I Yasunaga; S Toyokuni; M Matsuoka
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

7.  Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

Authors:  M Shimoyama
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

8.  Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.

Authors:  Cynthia A Pise-Masison; Michael Radonovich; Kathleen Dohoney; John C Morris; Deirdre O'Mahony; Min-Jung Lee; Jane Trepel; Thomas A Waldmann; John E Janik; John N Brady
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

9.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.

Authors:  Kunihiro Tsukasaki; Olivier Hermine; Ali Bazarbachi; Lee Ratner; Juan Carlos Ramos; William Harrington; Deirdre O'Mahony; John E Janik; Achiléa L Bittencourt; Graham P Taylor; Kazunari Yamaguchi; Atae Utsunomiya; Kensei Tobinai; Toshiki Watanabe
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.

Authors:  Rihab Nasr; Marwan E El-Sabban; José-Antonio Karam; Ghassan Dbaibo; Youmna Kfoury; Bertrand Arnulf; Yves Lepelletier; Françoise Bex; Hugues de Thé; Olivier Hermine; Ali Bazarbachi
Journal:  Oncogene       Date:  2005-01-13       Impact factor: 9.867
View more
  1 in total

1.  Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.

Authors:  Hua-Ping DU; Qian-Qian Yang; Y E Zhang
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.